Switch theme
Sign up to access all valuation multiples
Vuno Inc is engaged in the business of manufacturing medical devices and equipment. The company develops and markets bone age testing equipment, brain quantification medical device, X-ray reading aid solutions, imaging devices, and other related devices.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vuno has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Vuno achieved revenue of $17.6M and an EBITDA of -$7.4M.
Vuno expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vuno valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $9.0M | $17.6M | XXX | XXX | XXX |
| Gross Profit | $5.0M | $8.3M | XXX | XXX | XXX |
| Gross Margin | 56% | 47% | XXX | XXX | XXX |
| EBITDA | -$9.1M | -$7.4M | XXX | XXX | XXX |
| EBITDA Margin | -100% | -42% | XXX | XXX | XXX |
| Net Profit | -$10.7M | -$10.6M | XXX | XXX | XXX |
| Net Margin | -118% | -60% | XXX | XXX | XXX |
| Net Debt | n/a | $2.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Vuno's stock price is KRW 19900 (or $14).
Vuno has current market cap of KRW 276B (or $188M), and EV of KRW 276B (or $188M).
See Vuno trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $188M | $188M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Vuno has market cap of $188M and EV of $188M.
Vuno's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Vuno's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Vuno and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $188M | XXX | XXX | XXX |
| EV/Revenue | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | -25.3x | XXX | XXX | XXX |
| P/E | -21.2x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -23.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpVuno's NTM/LTM revenue growth is n/a
Vuno's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Vuno's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Vuno's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Vuno and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 95% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -42% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -18% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 68% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 20% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 145% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vuno acquired XXX companies to date.
Last acquisition by Vuno was XXXXXXXX, XXXXX XXXXX XXXXXX . Vuno acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Vuno founded? | Vuno was founded in 2014. |
| Where is Vuno headquartered? | Vuno is headquartered in South Korea. |
| Is Vuno publicy listed? | Yes, Vuno is a public company listed on KRX. |
| What is the stock symbol of Vuno? | Vuno trades under 338220 ticker. |
| When did Vuno go public? | Vuno went public in 2021. |
| Who are competitors of Vuno? | Similar companies to Vuno include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Vuno? | Vuno's current market cap is $188M |
| What is the current revenue growth of Vuno? | Vuno revenue growth between 2023 and 2024 was 95%. |
| Is Vuno profitable? | Yes, Vuno is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
